Weekly Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Ratings on May 3, 2018

May 3, 2018 - By Ronnie Lemelle

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Corporate Logo

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Ratings Coverage

Total analysts of 4 have positions in Bellicum Pharmaceuticals (NASDAQ:BLCM) as follows: 4 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since January 31, 2018 according to StockzIntelligence Inc Bellicum Pharmaceuticals has 5 analyst reports. On Wednesday, April 11 the stock has “Buy” rating by Cantor Fitzgerald. On Thursday, April 12 the stock of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) earned “Outperform” rating by Wells Fargo. On Wednesday, January 31 Wells Fargo downgraded the shares of BLCM in report to “Hold” rating. Listed here are Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) PTs and latest ratings.

11/04/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $18.0000 Maintain
12/04/2018 Broker: Wells Fargo Old Rating: Market Perform New Rating: Outperform Upgrade
16/02/2018 Broker: Citigroup Rating: Buy New Target: $27.0
31/01/2018 Broker: SunTrust Rating: Buy New Target: $18.0
31/01/2018 Broker: Wells Fargo Rating: Hold New Target: $6.0 Downgrade

Ticker’s shares touched $6.82 during the last trading session after 2.50% change.Bellicum Pharmaceuticals, Inc. has volume of 237,418 shares. Since May 3, 2017 BLCM has declined 43.51% and is downtrending. The stock underperformed the S&P500 by 55.06%.

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally.The firm is worth $229.37 million. The Company’s clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation.Last it reported negative earnings. The companyÂ’s preclinical product candidates include BPX-601, a GoCAR-T product candidate for treating solid tumors expressing the prostate stem cell antigen; and BPX-701, a T cell receptors product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma.

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: